A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

NCT04782076 ↗

Phase 1 Completed 36 enrolled Loxo Oncology, Inc. Eli Lilly and Company · collab

NaSequentialOpen-labelBasic science

Summary

The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib in healthy participants. This study will last approximately 22 to 25 days.

Timeline

Start: 2021-03-05
Primary completion: 2021-05-17
Completion: 2021-05-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran	Unknown	150 mg	Oral
Subject	Selpercatinib	Small molecule	160 mg	Oral

Indications

No indication recorded.